Company intelligence / Profile preview
Jaguar Gene Therapy
Lake Forest, Illinois, United Statesjaguargenetherapy.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has three preclinical programs: JAG101 for Type 1 galactosemia, JAG201 for genetic causes of autism spectrum disorder and Phelan-McDermid syndrome, and JAG301 for Type 1 diabetes. Encouraging preclinical proof-of-concept data has been produced for these programs[4][5].
- Therapeutic areas
- Metabolic DisordersEndocrinologyRare DiseasesPsychiatryNeurology
- Modalities
- Gene therapyAAV-based gene therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Broad Institute of MIT and HarvardEmory UniversityUniversity of UtahTulane University
Beyond the preview
Go deeper on Jaguar Gene Therapy.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jaguar Gene Therapy.